Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance

This study tests a drug called Poly-ICLC (Hiltonol), an immune-stimulating agent, injected both directly into the prostate tumor and given systemically in men with low-to-intermediate risk prostate cancer who are on active surveillance (watching the cancer closely without immediately treating it). **You may be eligible if...** - You are over 18 years old with confirmed low-grade or early intermediate-grade prostate cancer (Gleason 6 or 3+4) - You are currently on active surveillance and have not started any hormone therapy - Your life expectancy is at least 10 years - You would be a candidate for surgery or radiation if your cancer progresses - You have previously tolerated a prostate biopsy without serious complications **You may NOT be eligible if...** - You have high-grade prostate cancer - You have active autoimmune disease or immune deficiency - You are currently on immunosuppressive medications - You have had major pelvic surgery recently - You are unable to provide consent or comply with the study protocol Talk to your doctor to see if this trial is right for you.